Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Excessive renal uptake of prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals remains a major challenge in prostate cancer (PCa) detection and therapy. We developed 99mTc-labeled PSMA radioligands incorporating d- or l-proline as a conformationally constrained linker combined with optimized co-ligands to reduce kidney accumulation. The resulting hydrophilic complexes achieved high radiochemical yields and strong in vitro stability. The optimal radiotracer, [99mTc]Tc-L-M1, exhibited high LNCaP (PSMA++) cell affinity (Kd = 19.09 nM) and the lowest kidney uptake (6.50 ± 0.32% ID/g, Kunming mice, 2 h p.i.). It accumulated effectively in both LNCaP (PSMA++) and 22Rv1 (PSMA+) tumors with excellent target-to-nontarget ratios and strong PSMA specificity. SPECT/CT imaging confirmed low renal accumulation, consistent with biodistribution data. Preliminary clinical trials demonstrated clear delineation of small PCa lesions, highlighting [99mTc]Tc-L-M1 as a promising PSMA-specific radiotracer with reduced kidney uptake for clinical application.